Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

CNS Pharmaceuticals Presents Updated Safety Data From Ongoing Study Evaluating Berubicin In Advance Of The Pre-Planned Interim Analysis Of Efficacy

Author: Benzinga Newsdesk | November 22, 2023 10:09am

Data presented at the Society of NeuroOncology (SNO) 28th Annual Meeting

Berubicin currently being evaluated in an ongoing potentially pivotal study for the treatment of Glioblastoma Multiforme (GBM)

Topline result from preplanned interim futility analysis on track for December 2023

Posted In: CNSP